AZD-4017 is under clinical development by AstraZeneca and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AZD-4017’s likelihood of approval (LoA) and phase transition for Non Alcoholic Fatty Liver Disease (NAFLD) took place on 14 Feb 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 14 Feb 2022 decreased AZD-4017’s LoA and PTSR for Non-Alcoholic Steatohepatitis (NASH).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AZD-4017 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AZD-4017 overview

AZD-4017 is under development for the treatment of Cushing's syndrome, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The drug targets 11b-hydroxysteroid dehydrogenase 1 (11b-HSD1). It is administered orally as a tablet. It was also under development for the treatment of glaucoma, osteopenia, diabetes, obesity, idiopathic intracranial hypertension and post-menopausal osteopenia.

AstraZeneca overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

Quick View AZD-4017 LOA Data

Report Segments
  • Innovator
Drug Name
  • AZD-4017
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
  • Metabolic Disorders
  • Musculoskeletal Disorders
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.